|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4554545A
(en)
|
1980-10-30 |
1985-11-19 |
Mcdonnell Douglas Corporation |
Conformal head-up display
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
DE3343208A1
(de)
|
1983-11-30 |
1985-06-05 |
Bayer Ag, 5090 Leverkusen |
Neue cephalosporine und verfahren zu ihrer herstellung
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US4754065A
(en)
|
1984-12-18 |
1988-06-28 |
Cetus Corporation |
Precursor to nucleic acid probe
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
ES2052027T5
(es)
|
1988-11-11 |
2005-04-16 |
Medical Research Council |
Clonacion de secuencias de dominio variable de inmunoglobulina.
|
|
US5047335A
(en)
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
|
WO1990006952A1
(fr)
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Facteur de stimulation de colonies de granulocytes modifies chimiquement
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
WO1990007936A1
(en)
|
1989-01-23 |
1990-07-26 |
Chiron Corporation |
Recombinant therapies for infection and hyperproliferative disorders
|
|
EP0737750B1
(en)
|
1989-03-21 |
2003-05-14 |
Vical, Inc. |
Expression of exogenous polynucleotide sequences in a vertebrate
|
|
US6673776B1
(en)
|
1989-03-21 |
2004-01-06 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US6291158B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
|
EP0479909B1
(en)
|
1989-06-29 |
1996-10-30 |
Medarex, Inc. |
Bispecific reagents for aids therapy
|
|
DE3924128A1
(de)
|
1989-07-20 |
1991-01-31 |
Bosch Gmbh Robert |
Steuereinrichtung zum stillsetzen einer brennkraftmaschine
|
|
EP0487587A1
(en)
|
1989-08-18 |
1992-06-03 |
Chiron Corporation |
Recombinant retroviruses delivering vector constructs to target cells
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
NZ237464A
(en)
|
1990-03-21 |
1995-02-24 |
Depotech Corp |
Liposomes with at least two separate chambers encapsulating two separate biologically active substances
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
US6261774B1
(en)
|
1990-06-11 |
2001-07-17 |
Gilead Sciences, Inc. |
Truncation selex method
|
|
US5763566A
(en)
|
1990-06-11 |
1998-06-09 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: tissue SELEX
|
|
US5864026A
(en)
|
1990-06-11 |
1999-01-26 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: tissue selex
|
|
US5789157A
(en)
|
1990-06-11 |
1998-08-04 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: tissue selex
|
|
US5712375A
(en)
|
1990-06-11 |
1998-01-27 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: tissue selex
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
AU8507191A
(en)
|
1990-08-29 |
1992-03-30 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
|
US5278299A
(en)
|
1991-03-18 |
1994-01-11 |
Scripps Clinic And Research Foundation |
Method and composition for synthesizing sialylated glycosyl compounds
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
|
WO1993003769A1
(en)
|
1991-08-20 |
1993-03-04 |
THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES |
Adenovirus mediated transfer of genes to the gastrointestinal tract
|
|
CA2078539C
(en)
|
1991-09-18 |
2005-08-02 |
Kenya Shitara |
Process for producing humanized chimera antibody
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
EP0605522B1
(en)
|
1991-09-23 |
1999-06-23 |
Medical Research Council |
Methods for the production of humanized antibodies
|
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
|
WO1993010260A1
(en)
|
1991-11-21 |
1993-05-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
|
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
|
JP3949712B2
(ja)
|
1991-12-02 |
2007-07-25 |
メディカル リサーチ カウンシル |
抗体セグメントレパートリー由来でファージに表示される抗自己抗体の産生
|
|
PT1696031E
(pt)
|
1991-12-02 |
2010-06-25 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
JPH07507689A
(ja)
|
1992-06-08 |
1995-08-31 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
特定組織のターゲティング方法及び組成物
|
|
WO1993025698A1
(en)
|
1992-06-10 |
1993-12-23 |
The United States Government As Represented By The |
Vector particles resistant to inactivation by human serum
|
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
|
EP0656064B1
(en)
|
1992-08-17 |
1997-03-05 |
Genentech, Inc. |
Bispecific immunoadhesins
|
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
WO1994009817A1
(en)
|
1992-11-04 |
1994-05-11 |
City Of Hope |
Novel antibody construct
|
|
US6210671B1
(en)
|
1992-12-01 |
2001-04-03 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with L-selectin
|
|
JPH08503855A
(ja)
|
1992-12-03 |
1996-04-30 |
ジェンザイム・コーポレイション |
嚢胞性線維症に対する遺伝子治療
|
|
US5618829A
(en)
|
1993-01-28 |
1997-04-08 |
Mitsubishi Chemical Corporation |
Tyrosine kinase inhibitors and benzoylacrylamide derivatives
|
|
US5981568A
(en)
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
|
EP0695169B1
(en)
|
1993-04-22 |
2002-11-20 |
SkyePharma Inc. |
Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
|
|
US6838254B1
(en)
|
1993-04-29 |
2005-01-04 |
Conopco, Inc. |
Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
|
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
|
ATE304604T1
(de)
|
1993-06-24 |
2005-09-15 |
Frank L Graham |
Adenovirus vektoren für gentherapie
|
|
WO1995002420A2
(en)
|
1993-07-15 |
1995-01-26 |
Cancer Research Campaign Technology Ltd. |
Prodrugs of protein tyrosine kinase inhibitors
|
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
|
EP0711829A3
(en)
|
1993-09-15 |
1997-07-09 |
Viagene Inc |
Recombinant alphavirus vector
|
|
DE69434594T2
(de)
|
1993-10-25 |
2006-09-21 |
Canji, Inc., San Diego |
Rekombinante adenoviren-vektor und verfahren zur verwendung
|
|
JP3002702B2
(ja)
|
1993-11-16 |
2000-01-24 |
スカイファーム インコーポレーテッド |
活性物質の制御放出を有する小胞
|
|
SE9400088D0
(sv)
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
|
US6436908B1
(en)
|
1995-05-30 |
2002-08-20 |
Duke University |
Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
|
|
JP4303315B2
(ja)
|
1994-05-09 |
2009-07-29 |
オックスフォード バイオメディカ（ユーケー）リミテッド |
非交差性レトロウイルスベクター
|
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
WO1996017072A2
(en)
|
1994-11-30 |
1996-06-06 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6013443A
(en)
|
1995-05-03 |
2000-01-11 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: tissue SELEX
|
|
DE69633227T2
(de)
|
1995-05-03 |
2005-09-15 |
Gilead Sciences, Inc., Foster City |
Systematische evoultion von liganden durch exponentielle anreicherung: gewebe-selex
|
|
US5639757A
(en)
|
1995-05-23 |
1997-06-17 |
Pfizer Inc. |
4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
JP3370340B2
(ja)
|
1996-04-12 |
2003-01-27 |
ワーナー―ランバート・コンパニー |
チロシンキナーゼの不可逆的阻害剤
|
|
AU2998597A
(en)
|
1996-05-06 |
1997-11-26 |
Chiron Corporation |
Crossless retroviral vectors
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
WO1998052976A1
(en)
|
1997-05-21 |
1998-11-26 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
US6100254A
(en)
|
1997-10-10 |
2000-08-08 |
Board Of Regents, The University Of Texas System |
Inhibitors of protein tyrosine kinases
|
|
US6376471B1
(en)
|
1997-10-10 |
2002-04-23 |
Johns Hopkins University |
Gene delivery compositions and methods
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
GB9901441D0
(en)
|
1999-01-23 |
1999-03-10 |
Dolcan Limited |
Crossbows
|
|
US6740665B1
(en)
|
1999-02-10 |
2004-05-25 |
Ramachandran Murali |
Tyrosine kinase inhibitors and methods of using the same
|
|
CA2364484A1
(en)
|
1999-03-09 |
2000-09-14 |
University Of Southern California |
Method of promoting myocyte proliferation and myocardial tissue repair
|
|
US6245759B1
(en)
|
1999-03-11 |
2001-06-12 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2001000207A1
(en)
|
1999-06-30 |
2001-01-04 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
|
AU5636900A
(en)
|
1999-06-30 |
2001-01-31 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
|
JP2003503354A
(ja)
|
1999-06-30 |
2003-01-28 |
メルク エンド カムパニー インコーポレーテッド |
Ｓｒｃキナーゼ阻害剤化合物
|
|
US6387620B1
(en)
|
1999-07-28 |
2002-05-14 |
Gilead Sciences, Inc. |
Transcription-free selex
|
|
US6334459B1
(en)
|
1999-08-11 |
2002-01-01 |
Leon Berger |
Multi-fuctional brake bleeder tool
|
|
BR0013899A
(pt)
|
1999-09-10 |
2003-07-08 |
Merck & Co Inc |
Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral
|
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
|
KR100681724B1
(ko)
|
1999-10-19 |
2007-02-28 |
머크 앤드 캄파니 인코포레이티드 |
티로신 키나제 억제제 및 이를 포함하는 약제학적 조성물
|
|
US6794393B1
(en)
|
1999-10-19 |
2004-09-21 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
JP2003512353A
(ja)
|
1999-10-19 |
2003-04-02 |
メルク エンド カムパニー インコーポレーテッド |
チロシンキナーゼ阻害剤
|
|
US6420382B2
(en)
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6313138B1
(en)
|
2000-02-25 |
2001-11-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2002061087A2
(en)
|
2000-12-19 |
2002-08-08 |
Lifespan Biosciences, Inc. |
Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
|
|
US20050053973A1
(en)
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US20050089932A1
(en)
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US20060223114A1
(en)
|
2001-04-26 |
2006-10-05 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
|
JP4369662B2
(ja)
|
2001-04-26 |
2009-11-25 |
アビディア インコーポレイテッド |
単量体ドメインのコンビナトリアルライブラリー
|
|
US20030157561A1
(en)
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
|
US20050048512A1
(en)
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
|
US20040175756A1
(en)
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
|
AU2002346053B2
(en)
|
2001-06-22 |
2008-03-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
AU2002319402B2
(en)
|
2001-06-28 |
2008-09-11 |
Domantis Limited |
Dual-specific ligand and its use
|
|
WO2003011836A1
(en)
|
2001-08-01 |
2003-02-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
CA2456928A1
(en)
|
2001-08-10 |
2003-02-20 |
Topigen Pharmaceutique Inc. |
Cellular virus receptors and methods of use
|
|
US6927293B2
(en)
|
2001-08-30 |
2005-08-09 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
DE60226641D1
(de)
|
2001-12-03 |
2008-06-26 |
Amgen Fremont Inc |
Antikörperkategorisierung auf der grundlage von bindungseigenschaften
|
|
EP1600459A3
(en)
|
2002-06-28 |
2005-12-07 |
Domantis Limited |
Ligand
|
|
EP2270048B1
(en)
|
2002-12-24 |
2015-11-11 |
Rinat Neuroscience Corp. |
Anti-NGF antibodies and methods using same
|
|
JP2006523090A
(ja)
|
2002-12-27 |
2006-10-12 |
ドマンティス リミテッド |
リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
|
|
US20090005257A1
(en)
|
2003-05-14 |
2009-01-01 |
Jespers Laurent S |
Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
|
|
SI1639011T1
(sl)
|
2003-06-30 |
2009-04-30 |
Domantis Ltd |
Pegilirana protitelesa z enojno domeno (dAb)
|
|
WO2005040229A2
(en)
|
2003-10-24 |
2005-05-06 |
Avidia, Inc. |
Ldl receptor class a and egf domain monomers and multimers
|
|
US20060008844A1
(en)
|
2004-06-17 |
2006-01-12 |
Avidia Research Institute |
c-Met kinase binding proteins
|
|
EP1824796A4
(en)
|
2004-11-16 |
2010-02-17 |
Avidia Res Inst |
PROTEIN SKELETONS AND USES THEREOF
|
|
CA2597717C
(en)
*
|
2005-02-18 |
2014-10-21 |
Dana-Farber Cancer Institute |
Antibodies against cxcr4 and methods of use thereof
|
|
US7314622B2
(en)
|
2005-04-15 |
2008-01-01 |
Neogenix Oncology, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
|
WO2006126188A2
(en)
*
|
2005-05-25 |
2006-11-30 |
Hadasit Medical Research Services And Development Ltd. |
Cxcr4 antagonists for wound healing and re-epithelialization
|
|
WO2007038619A2
(en)
|
2005-09-27 |
2007-04-05 |
Amunix, Inc. |
Proteinaceous pharmaceuticals and uses thereof
|
|
US10155816B2
(en)
|
2005-11-28 |
2018-12-18 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
|
US7964191B2
(en)
*
|
2006-02-02 |
2011-06-21 |
Allergan, Inc. |
Compositions and methods for the treatment of ophthalmic disease
|
|
ES2625798T3
(es)
*
|
2006-10-02 |
2017-07-20 |
E. R. Squibb & Sons, L.L.C. |
Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
|
|
WO2009074807A2
(en)
*
|
2007-12-12 |
2009-06-18 |
Imperial Innovations Limited |
Methods
|
|
EP2172485A1
(en)
*
|
2008-10-01 |
2010-04-07 |
Pierre Fabre Medicament |
Novel anti CXCR4 antibodies and their use for the treatment of cancer
|
|
CA2779796A1
(en)
|
2009-11-04 |
2011-05-12 |
Dsm Ip Assets B.V. |
Talaromyces transformants
|
|
EP2371863A1
(en)
*
|
2010-03-30 |
2011-10-05 |
Pierre Fabre Médicament |
Humanized anti CXCR4 antibodies for the treatment of cancer
|
|
EP2569337A1
(en)
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
CA2930801C
(en)
|
2010-11-05 |
2019-05-28 |
Rinat Neuroscience Corporation |
Engineered polypeptide conjugates and methods for making thereof using transglutaminase
|
|
US20140120555A1
(en)
*
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
|
TWI589592B
(zh)
|
2011-11-17 |
2017-07-01 |
輝瑞股份有限公司 |
胞毒性肽類以及其抗體藥物共軛體
|
